Tc-99m MDP Uptake in a Calcified Untreated Non-Hodgkin's Lymphoma of Spleen

Kim, Pora; Turoğlu, Halil Turgut; Mf, Akisik; Naddaf, Sleiman; Ws, Omar; Hm, Abdel-Dayem

doi:10.1097/00003072-199705000-00024

Cited by 4 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These drugs may also be located in the calcified matrix outside the bone and have been found in calcified atherosclerotic plaques in animals and humans 21–24. The accumulation of bisphosphonates in atherosclerotic arteries is probably due to bisphosphonates connection with calcified atheromatous lesions, as it is well known that these drugs have high affinity for calcium and hydroxyapatite.…”

Section: Introductionmentioning

confidence: 99%

“…21 These drugs may also be located in the calcified matrix outside the bone and have been found in calcified atherosclerotic plaques in animals and humans. [21][22][23][24] The accumulation of bisphosphonates in atherosclerotic arteries is probably due to bisphosphonates connec tion with calcified atheromatous lesions, as it is well known that these drugs have high affinity for calcium and hydroxyapatite. However, the bisphosphonates etidronate and pamidronate were found in high concentrations in aortas without atherosclerotic lesions in mice and in healthy human mammary arteries.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Vascular Effects of Bisphosphonates–-A Systematic Review

Santos

Cavalcanti

Bandeira

2012

Clin Med Insights Endocrinol Diabetes

View full text Add to dashboard Cite

Background:Osteoporosis and cardiovascular disease are interconnected entities with pathophysiological similarities. Bisphosphonates are therapeutic options available for resorptive bone diseases; however, experimental evidence has demonstrated a role for bisphosphonates in the inhibition of atherogenesis.Methods:A systematic review of the vascular effects of bisphosphonates on atherosclerosis was performed. Vascular effects were evaluated by the thickening of the intima-media of carotid arteries and calcification of the coronary and aorta arteries. Electronic databases PubMed, The Cochrane Library, and Embase from January 1980 to May 2011 were searched.Results:Of 169 potentially relevant articles, 9 clinical trials were selected. Two articles showed the benefit of the use of etidronate (−0.038 mm, P < 0.005) and alendronate (−0.025 mm, P < 0.05) on carotid artery intima-media thickening (CIMT) after one year. One article found no changes associated with the use of alendronate. The use of risedronate was associated with a reduction of plaque score on the carotid arteries (decrease of 1% at 1 year, P = 0.015). Of those studies that evaluated the effect on coronary artery calcification (CAC), the results are conflicting: one study showed no changes with use of etidronate and in another, etidronate resulted in inhibition of the process of CAC after 1 year of follow-up (−372 mm3 in CAC score, P < 0.01). Three studies showed positive effects of etidronate on the aortic calcificaton (AC) score, showing no effect with use of ibandronate, and another showed a inhibition in the progression of the abdominal AC score with use of risendronate (P = 0.043).Conclusion:Bisphosphonates seem to have an inhibitory effect on the atherosclerotic process; however, larger placebo-controlled studies are needed to better clarify this issue.

show abstract

Section: Introductionmentioning

confidence: 99%